Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | Retaspimycin is a potent and water-soluble Hsp90 inhibitor(EC50s of 119 nM for both Hsp90 and Grp9). |
Targets&IC50 | HSP90:119 nM (EC50), Grp94:119 nM (EC50) |
In vitro | Retaspimycin is a potent Hsp90 inhibitor(EC50s of 119 nM for both Hsp90 and Grp9). Retaspimycin is cytocoxic to human multiple myeloma (MM) cell lines(EC50s of 307 ± 51 nM and 306 ± 38 nM, respectively, for MM1.s and RPMI-8226 cells)[1]. Retaspimycin (IPI-504, 10-100 nM) suppresses the growth of both trastuzumab-sensitive and -resistant cells in a dose-dependent manner. Retaspimycin (0-500 nM) decreases HER2 protein expression and suppresses both Akt and MAPKs pathways in both sensitive and trastuzumab-resistant cells[3]. |
In vivo | selective tumor retention in RPMI-8226 tumor-bearing mice caused by Retaspimycin. The tumor volume by 69% and and 84% of baseline values in GIST-882 and GIST-PSW xenografts reduced by Retaspimycin, respectively. Furthermore, Retaspimycin in combination with imatinib inhibits tumor growth more significantly than Retaspimycin alone in GIST-PSW model, but no obvious difference is ovsrebed in the GIST-882 model. Retaspimycin also downregulates KIT in gastrointestinal stromal tumor (GIST)[2] |
Molecular Weight | 587.7 |
Formula | C31H45N3O8 |
Cas No. | 857402-23-4 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.